NY-AQARA
11.7.2022 09:02:05 CEST | Business Wire | Press release
Aqara, a leading provider of smart home products, announced the wide availability of its Curtain Driver E1, a retrofit solution to automate traditional curtains. Build upon the Zigbee 3.0 protocol with improved reliability, range and energy efficiency, the curtain driver features a battery life of up to 12 months between each charge1 , and connects with other smart home accessories to enable truly automated home experiences2 . The Curtain Driver E1 has been made available on Amazon in both North America (US , Canada ) and Europe (UK , France , Germany , Italy , Spain ), as well as via selective Aqara retailers worldwide3 .
With two variants, namely the Rod Version for rods and the Track Version for U-rails and I-rails, the Aqara Curtain Driver E1 are compatible with a majority of curtains on the market. Thanks to its quiet-yet-powerful motor, heavier curtains of up to 12 kilograms can be pulled. It also features a wide compatibility with third-party ecosystems and voice assistants, including HomeKit/Siri, Alexa, Google Home/ Google Assistant, IFTTT, and the upcoming Matter standard will also be supported after its roll-out4 .
The installation is easy. Just mount the Curtain Driver E1 onto the curtain rod or rail, and no additional tools are required. The retrofit solution requires no new wiring to motorize the curtains, and the 6000mAh battery - which lasts for up to 1-year of use - can be charged via the Type-C port. It’s equipped with a built-in light sensor, allowing the curtain to close by its own when it’s too bright, and vice versa.
Apart from ambient brightness, the Curtain Driver can also be smartly controlled by other conditions, such as pre-set schedules, sunrise/sunset, local weather, and geofencing. For example the curtains open at sunset so that the beautiful view won’t be missed. When connect with other Aqara devices, more possibilities are made possible. Use a Wireless Mini Switch to open, close or stop the curtain by a simple press, or adjust the precise opening by turning the Cube. The Camera Hub G3 even allows the curtain to be controlled with hand gestures.
The Curtain Driver is designed with high flexibility to suit for different scenarios and use cases. Device grouping is supported, so that double sided curtains can be controlled simultaneously. The speed of the curtain driver is adjustable, and the device can be configured to work more quietly in the mornings so that the sleep won’t be interrupted anymore. Moreover, it’s possible to set the duration time for curtain movements, for example to pull the curtain from closed to fully open in an hour, which simulates a natural sunrise.
In celebration of the launch, Aqara now offers a 20% discount for the new device on Amazon. North American customers will enjoy the offer with the promo code USCURTAIN in the US and Canada , while European customers will enjoy it using the promo code CURTAINUKEU in France , Germany , Italy , Spain and the UK . Both codes are valid on July 11th , 2022. And Amazon Prime members will continue to enjoy the discount from July 12th to 13th with no promo code required.
For more details of the Curtain Driver E1, please visit our website .
1. Based on the lab test of two devices on the double panel curtains. The actual battery life may vary, depending on curtain weight, track length, and friction.
2. A Zigbee 3.0 Aqara hub is required.
3. Product availability may vary among different retail channels, and could be updated all the time. It’s recommended to check with the regional retailer(s) for real time availability.
4. An OTA update of the compatible Aqara hub is required.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220711005076/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom